Article debunks claims that gene editing will revolutionise crop breeding in Africa
By Claire Robinson,
GMWatch
| 01. 24. 2023
Gene editing has captured the imagination of academics and professionals working on agricultural development in Africa. They claim the technology has the potential to revolutionise crop breeding, based on assertions of precision, cheapness and speed.
However, these claims are strongly challenged in a new peer-reviewed article by an international group of development experts led by Joeva Sean Rock, Professor of Development Studies at the University of Cambridge, UK. The authors review the evidence and experience of older-style GM crops in Africa, as well as the research findings to date on gene editing. They conclude that unless hard lessons are learned from experience with first-generation GM crops, gene editing projects "are in danger of repeating mistakes of the past".
The article is open access and written in an easy-to-understand style, and we recommend reading it in full.
We've heard it before
The authors find that the narratives around gene editing closely echo the earlier ones underpinning the introduction of older-style GM crops into Africa: "But the reality of GM crops in Africa has not lived up to the hype". Problems include...
Related Articles
By Maggie Astor, The New York Times | 06.23.2026
Every year, patients undergo millions of in vitro fertilization procedures worldwide. Only a minority result in a live birth.
In an effort to improve the odds, scientists have developed an array of “add-ons” that could in theory identify the most...
By Carl Zimmer and Catrin Einhorn, The New York Times | 06.25.2026
The Trump administration and a company that is promising to bring long-gone animals back from extinction announced a partnership on Thursday to preserve cells, tissue and DNA from threatened and endangered species.
The company, Colossal Biosciences, said its goal was...
By Marisa Flook , BioNews | 06.29.2026
An anti-ageing gene therapy not approved by the US Food and Drug Administration (FDA) is set to be offered by an American company at overseas clinics outside of US jurisdiction.
The treatment, developed by Minicircle from Austin, Texas, uses a...
By Philip Ball , Nature | 06.17.2026
Our genomes are full of mutations that have the potential to damage our health or even kill us. Yet most of them rarely cause problems. Why? It’s partly thanks to a family of proteins that mask, or ‘buffer’, the ill...